Adjusting for treatment switching in randomised controlled trials

PSI European Statistical Meeting: Latest Trends in Health Technology Assessments
28th November 2017

Nicholas Latimer, University of Sheffield, Sheffield, UK, Senior Research Fellow in Health Economics, NIHR Post Doctoral Research Fellow

Thanks to Ian White, who I run a course with on this. Some of my slides have borrowed from his
Health economic evaluation and HTA

- Economic evaluation plays an important role in HTA. Aim to ensure limited health care budget is allocated efficiently
- This means that the benefits of programmes that are implemented must exceed their opportunity costs
- Need to compare the new treatment to all relevant comparators
- Usually involves a comparison of the costs and effects of the new treatment and the standard treatment
  - Decision problem: compare state of the world where the new treatment exists, to state of the world where new treatment does not exist
- Usually information to make these comparisons is taken from randomised controlled trials using an intention to treat analysis
Treatment switching

- What if patients randomised to the control group in a clinical trial are permitted to switch onto the experimental treatment at some point during the trial?
Illustrating treatment switching

Control Treatment

- PFS
- PPS

Intervention

- PFS
- PPS

Control $\rightarrow$ Intervention

- PFS
- PPS

Survival time

True OS difference

RCT OS difference

PFS: Progression-free survival; PPS: Post-progression survival; OS: Overall survival
Treatment switching

- Is an issue in over 50% of oncology technology assessments
  - This is a problem for decision-makers who rely on ITT analyses
  - Need different analytical methods
  - Adjustment methods can change decisions

NICE TA321 Dabrafenib for melanoma
57% switched
ITT analysis: OS HR 0.76; ICER £95,225
Adjustment analysis: OS HR 0.55; ICER £49,019
- Dabrafenib was recommended for use

... so what’s the problem?
Treatment switching

...different adjustment methods are available...

...and they might give different results

TA 215, Pazopanib for RCC [51% of control switched]

- **ITT:** OS HR (vs IFN) = 1.26 → ICER = Dominated
- **Censor switchers:** HR = 0.80 → ICER = £71,648
- **Exclude switchers:** HR = 0.48 → ICER = £26,293
- **IPCW:** HR = 0.80 → ICER = £72,274
- **RPSFTM (weighted):** HR = 0.63 → ICER = £38,925

(Note, ITT did not include baseline covariates, RPSFTM did…)

As well as IPCW and RPSFTM, two-stage adjustment has been used in HTA to adjust for switching

- We need an understanding of the methods, so we can decide which one to believe, on a case-by-case basis

- But first…
Types of switching

1. Switching from the control onto the experimental treatment
   - ‘Direct’ switching

2. Switching from the experimental onto the control
   - ‘Direct’ switching

3. Switching from control/experimental onto other treatments
   - ‘Indirect’ switching

What it is relevant to adjust for depends upon our decision problem (this is not always straightforward!)
Types of switching

‘Direct’ switching

- HTA decision problem typically = comparison two “states of the world”:
  a) State of the world in which the new intervention exists (State A)
  b) State of the world in which the new intervention does not exist (State B)

- State B should not be contaminated by the new intervention

► We need to adjust if control group patients receive the new treatment
Types of switching

‘Direct’ switching

- HTA decision problem typically = comparison two “states of the world”:
  a) State of the world in which the new intervention exists (State A)
  b) State of the world in which the new intervention does not exist (State B)

- State B should not be contaminated by the new intervention

  ➔ We need to adjust if control group patients receive the new treatment

- **BUT**, If control treatment represents a standard therapy (or placebo/BSC), it will be available in State A and State B

  ➔ Switching from the new treatment to the control treatment (due to lack of efficacy/toxicity etc.) may represent a realistic treatment pathway in both states of the world

  ➔ We (usually) do not need to adjust if experimental group patients receive the control treatment
Types of switching

‘Indirect’ switching

- Situation less clear if patients (in either group) receive other post-study treatments
- If these are available in the real world, they may represent realistic treatment pathways within both states of the world → unnecessary/undesirable to adjust
- If these include other experimental treatments that are not available in the real world, they may represent unrealistic treatment pathways within both states of the world → necessary/desirable to adjust
What do we need to adjust for?

1. Switching from the control onto the experimental treatment
   - ‘Direct’ switching

2. Switching from the experimental onto the control
   - ‘Direct’ switching

3. Switching from control/experimental onto other treatments
   - ‘Indirect’ switching

What it is relevant to adjust for depends upon our decision problem
Adjustment methods – a summary

- When we want to adjust for treatment switching we have the following options

- Exclude/censor switchers
  - Weak in simple settings
  - But can elaborate it → IPCW

- Model treatment effect after switch → Two-stage

- Model treatment effect → RPSFTM
IPCW

Idea is to extend simple per protocol censoring analysis to remove selection bias.

Four steps:

1. Censor switchers at point of switch
2. Model probability of switching according to baseline and time-dependent characteristics → No unmeasured confounding
3. Use probabilities to compute weights (e.g. upweight people who have similar characteristics to switchers but didn’t switch)
4. Use weights in a survival analysis to remove selection bias associated with censoring
Two-stage adjustment

Idea is to estimate the treatment effect associated with switching, allowing us to derive what would have happened in the absence of switching.

Applicable when switching happens after a specified disease-related time-point (e.g. disease progression).

Three steps…
Two-stage adjustment

1. Identify secondary baseline in control group

2. Estimate post-secondary baseline treatment effect in switchers compared to non-switchers using an AFT model

3. “Shrink” survival times in switchers according to the AF, deriving counterfactual survival times

No unmeasured confounding
Like the two-stage method, estimate treatment effect associated with switching, allowing us to derive what would have happened in the absence of switching.

But, doesn’t distinguish between the treatment effect in switchers and the treatment effect in the experimental group.

- Doesn’t need the NUC assumption, but…

1. Assume perfect randomisation: no treatment, equal average survival
2. Assume there is a common treatment effect
3. Use g-estimation and a counterfactual survival model to identify a value for the treatment effect that gives equal untreated survival times between randomised groups – hence derive untreated survival times for switchers

Identifying appropriate methods

It is not easy to identify the “best” method. Different methods will be best in different circumstances. We need to consider:

1. Methodological assumptions: Are they plausible?

2. Practical issues: Has the analysis “worked”? How (exactly) has it been applied?

## Simulation study findings

| RPSFTM / IPE produce low bias when treatment effect is common | → But are very sensitive to this, especially when the treatment effect is high |
| IPCW is volatile in (relatively) small trial datasets | → Especially when switching % is very high (leaving low $n$ in control group) |
| Simple two-stage methods are worthy of consideration |
| Very important to assess trial data, switching mechanism, treatment effect to determine which method likely to be most appropriate |
| There is a requirement for clinical opinion, to determine justifiable methods |

→ Don’t just pick one!!
Adjustment methods and HTA

- Adjustment analyses are becoming increasingly common in HTA
- Several HTA agencies are ready to adopt them
  - NICE, PBAC and SMC
  - IQWiG

**BUT…**
- Adjustment analyses not always accepted – case-by-case basis
- Concerns are with assumptions that cannot be perfectly tested
- And potential scope for “selective” analyses (within methods, and also around what to adjust for)
  - Which covariates are used in IPCW? Which AFT model is used in two-stage?
  - Is re-censoring incorporated in two-stage / RPSFTM? Direct and indirect switching?
- Sometimes results seem to lack clinical validity

→ NICE and PBAC have published technical guides (e.g. see Latimer N, Abrams K. NICE DSU Tech Support Doc 16, 2014)
Adjustment methods and regulatory

- Adjustment analyses are rarely a feature in regulatory submissions

- But FDA and EMA have both been actively involved in international workshops discussing the topic (Adelaide, Baltimore)

- Addendum to ICH E9 seems to make the case that analyses to adjust for switching are justifiable

- Perhaps these will begin to feature more in the future?
Conclusions

- Treatment switching is a common issue in HTA
- Standard ITT analyses may not answer the question HTA decision-makers are interested in
- Adjustment methods represent an answer and are being used (in some places, with caution)
- Some decision makers are *not* using these methods and some analyses are poor – there is a need to improve quality
- Adjustment methods must be appropriately justified and described, and precedent is not enough